Dr. Andrew Rudd is the Cofounder and CEO of Palm Therapeutics. Dr. Rudd’s career has centered around developing chemical tools to interrogate biological lipids and their roles in health and disease. He received his Ph.D. in chemistry from UC San Diego where he developed chemical tools for the study of biological lipids. During his graduate work, Dr. Rudd developed the first small molecule probes for directly inhibiting protein palmitoylation in cells. In 2021, Dr. Rudd launched Palm Therapeutics at JLABS San Diego with the mission of developing the first palmitoylation-targeted therapies. Palm has received multiple NIH SBIR grants, was the recipient of the 2023 Servier Discovery Award, and has been recognized as a 2024 Connect Cool Company.